Petar Seferovic, Andrew Coats, Gerasimos Filippatos, Johann Bauersachs, Giuseppe Rosano, Stefan Anker

The Esc Textbook of Heart Failure

• Gebundenes Buch

Produktbeschreibung

The ESC Textbook of Heart Failure brings together renowned experts to present an up-to-date understanding of all aspects of this chronic condition. The clinically oriented work reflects guidelines and summarizes the latest evidence from clinical trials. A must read for cardiovascular healthcare specialists in Europe and across the world.

Produktdetails

• Verlag: Oxford University Press, USA
• Seitenzahl: 1040
• Erscheinungstermin: 9. Februar 2024
• Englisch
• Abmessung: 277mm x 244mm x 66mm
• Gewicht: 2767g
• ISBN-13: 9780198891628
• ISBN-10: 0198891628
• Artikelnr.: 68543646

Inhaltsangabe

* Section 1: Universal definition of heart failure
* 1.1: Andrew JS Coats, Biykem Bozkurt and Petar M. Seferovic:
Universal definition of heart failure
* Section 2: Epidemiology of heart failure
* 2.1: Amy Groenewegen, Ivan Milinkovi?, Arno W Hoes, Arend Mosterd,
Frans H Rutten: Epidemiology of heart failure
* Section 3: Etiology of heart failure
* 3.1: (Rocco Antonio Montone, Maurizio Volterrani, Jian Zhang and
Filippo Crea: Coronary artery disease
* 3.2: Athanasios Manolis and Yuri Lopatin: Hypertension
* 3.3: Ana Pardo Sanz, Ivan Milinkovic and Josep Zamorano: Valvular
heart disease
* 3.4.1: Thomas Thum, Stephane Heymans, and Johannes Backs: Genetic
basis of cardiomyopathies
* 3.4.2: Petar M.Seferovic, Biykem Bozkurt, and Marija Polovina:
Dilated and hypokinetic non-dilated cardiomyopathy
* 3.4.3: Perry Elliott, Michel Noutsias and Aris Anastasakis:
Hypertrophic cardiomyopathy
* 3.4.4: Claudio Rapezzi, Alberto Aimo, Ales Linhart, and Andre Keren:
Restrictive cardiomyopathy
* 3.4.5: Cristina Basso, Hugh Calkins and Domenico Corrado:
Arrhythmogenic right ventricular cardiomyopathy
* 3.4.6: Karen Sliwa and Johann Bauersachs: Peripartum cardiomyopathy
* 3.4.7: Jelena Templin-Ghadri, Michael Würdinger, Johann Bauersachs,
and Christian Templin: Takotsubo cardiomyopathy
* 3.5: Stephane Heymans, Arsen Risti?, Yehuda Adler, and Massimo
Imazio: Myocarditis and pericarditis
* 3.6: Werner Budts and Jolien Roos-Hesselink: Congenital heart disease
* 3.7: Martin Huelsmann, Jelena Seferovic and Francesco Cosentino:
Endocrine and metabolic disorders
* 3.8: Lina Badimon, Stefan Anker and Stephan von Haehling: Obesity
* 3.9: Alexander Lyon, Dimitrios Farmakis, Daniela Cardinale and Teresa
Lopez Fernandez: Cancer and cancer therapy
* 3.10: Antonello Gavazzi, Maria Nunes, and Fausto Pinto: Toxins (e.g.
alcohol etc.) and infections
* Section 4: Prevention of heart failure
* 4.1: Massimo Piepoli, Maria Benedetta Matrone, Paul Dendale, and
Shelley Zieroth: Prevention of heart failure
* Section 5: Pathophysiology of heart failure
* 5.1: (Junjie Xiao, Thomas Thum, Gianluigi Condorelli and Johannes
Backs: Molecular and cellular mechanisms
* 5.2: Edoardo Bertero and Chistoph Maack: Alterations in myocardial
metabolism
* 5.3: Javier Diez Martinez and Hans-Peter Brunner La Rocca:
Ventricular remodelling
* 5.4: Antoni Bayes Gennis and Faiez Zannad: Neurohormonal activation
* 5.5: Urlich Hofmann, Stefan Frantz and Nikolaos Frangogiannis:
Immune-mediated mechanisms
* 5.6: Stephane Heymans: Inflammation, oxidative stress and endothelial
dysfunction
* 5.7: Alterations in peripheral circulation and renal function (:
Alterations in peripheral circulation and renal function
* 5.8: (Stephan von Haehling and Wolfram Doehner: Systemic adaptations
in metabolism and nutritive status
* Section 6: Clinical phenotypes of chronic heart failure
* 6.1: Thomas Luscher, Petar Seferovic, and Brian Halliday: HFrEF
* 6.2: Adrian Voors, Brenda Moura, Lars Lund and Carolyn Lam: HFmrEF
* 6.3: Rudolf De Boer, Burkert Pieske, and Barry Borlaug: HFpEF
* 6.4: Thomas Luscher, Thomas M. Gorter, Susanna Price, Michael
Gatzoulis and Anneline Te Riele: Right heart failure
* Section 7: Chronic heart failure: diagnostic and prognostic
assessment
* 7.1: Michel Komajda, Piotr Ponikowski, and Evgeny Shlyakhto: Clinical
assessment
* 7.2: Rudolf de Boer, Antioni Bayes Genis and James Januzzi:
Biomarkers in diagnostic and prognostic assessment
* 7.3: Philippe Debonnaire, Victoria Delgado, Thor Edvardsen, Bogdan
Popescu, and Jeroen Bax: Echocardiography
* 7.4: Danilo Neglia and Alessia Gimelli: Nuclear medicine
* 7.5: Stephan Achenbach and Amina Rakisheva: Cardiac computed
tomography
* 7.6: Anna Baritussio, Noor Sharrack, Sven Plein, and Chiara
Bucciarelli-Bucci: Cardiac magnetic resonance
* 7.7: Luca Moderato, Davide Lazzeroni, Stamatis Adamopoulos, Alain
Cohen-Solal and Massimo Piepoli: Cardiopulmonary exercise
* 7.8: Christian Hamm, Brigit Assmus and Veselin Mitrovic: Cardiac
catheterization, invasive imaging and haemodynamic assessment
* Section 8: Chronic heart failure: pharmacological management
* 8.1: Roberto Ferrari, Gabriele Guardigli, and Biykem Bozkurt:
Angiotensin converting enzyme inhibitors
* 8.2: Ileana L. Pina and Magdy Abdelhamid: Angiotensin I receptor
blockers
* 8.3: Petar M. Seferovic, Michele Senni, Marija Polovina and Andrew JS
Coats: ARNI
* 8.4: Daniela Tomasoni, Marianna Adamo, Hiroyuki Tsutsui, and Marco
Metra: Beta-blockers
* 8.5: Bertram Pitt, João Pedro Ferreira and Faiez Zannad:
Mineralocorticoid receptor agonists
* 8.6: Michael Bohm and Michel Komajda: Ivabradine
* 8.7: Eftihia Polyzogopoulou, Maria Nikolaou, John Parissis and
Alexandre Mebazaa: Vasodilators
* 8.8: Udo Bavendiek and Johann Bauersachs: Digitalis glycosides
* 8.9: Jeroen Dauw, Stephen Gottlieb and Wifried Mullens: Diuretics
* 8.10: Jan Biegus, Piotr Ponikowski, and Christoph Maack: Inotropes
and inodilators
* 8.11: Petar M. Seferovic, Francesco Cosentino, Giuseppe Rosano and
James Januzzi: SGLT2 inhibitors
* 8.12: Stefan Agewall, Isabelle van Gelder, and Irene Savelieva:
Ancillary pharmacological treatment options
* 8.13: Giuseppe Rosano, Gerasimos Filippatos, and Randall Starling:
New and emerging therapies
* Section 9: Chronic heart failure: non-pharmacological management
* 9.1: Gianluigi Savarese, Cecilia Linde and Kenneth Dickstein:
Implantable cardioverter defibrillator
* 9.2: Pieter Martens, Eva Goncalvesova, and Wilfried Mullens: Cardiac
resynchronization therapy
* 9.3: Felix Schoenrat, Franz-Josef Neumann, Miguel Sousa Uva and
Volkmar Falk: Cardiac surgery
* 9.4: Stefan Orwat, Stefan Anker and Helmut Baumgartner: Valve
interventions
* 9.5: Andrew JS Coats, Piotr P Ponikowski, Maria-Rosa Costanzo and
William T. Abraham: Ancillary procedures
* 9.6: Maurizio Volterrani, Alain Cohen-Solal, Stamatis Adamopulos,
Dimitris Miliopoulos, Ferdinando Iellamo, and Massimo Piepoli:
Cardiac rehabilitation
* Section 10: Acute heart failure
* 10.1: Ovidiu Chioncel, Gerasimos Filippatos, Alexandre Mebazaa,
Veli-Pekka Harjola, and Josep Masip: Acute heart failure: diagnostic
and prognostic assessment
* 10.2: Katerina Fountoulaki, John Parissis, Sean Collins, Mehmet
Birhan Yilmaz, and Alexandre Mebazaa: Acute heart failure: management
* Section 11: Advanced heart failure
* 11.1: Tuvia Ben Gal, Mariell Jessup, and Maria-Rosa Costanzo:
Advanced heart failure: assessment
* 11.2: Daniela Tomasoni, Marianna Adamo, and Marco Metra: Advanced
heart failure: management
* 11.3: Mandeep Mehra and Finn Gustafsson: Mechanical circulatory
support
* 11.4: Davor Milicic, Mandeep Mehra, and Randall Starling: Heart
transplantation
* 11.5: Tiny Jaarsma, Donna Fitzsimons, Lisa Hjelmfors, Loreena Hill,
Ekaterini Lambrinou, and Anna Strömberg: Palliative care and
end-of-life management
* Section 12: Comorbidities and clinical conditions
* 12.1: Pieter Martens and Hans-Peter Brunner-La Rocca: Chronic kidney
disease: Clinical Aspects of Chronic Kidney Disease in Heart Failure
* 12.2: Javed Butler, Wilfried Mullens and Kevin Damman and João Pedro
Ferreira: Dyskalaemia
* 12.3: Josep Masip, Karina Portillo and Mattia Arrigo: Chronic lung
disease
* 12.4: Piergiuseppe Agostoni, Elisabetta Salvioni, Maria Rosa
Costanzo, and Andrew JS Coats: Ventilatory Abnormalities and Sleep
Disordered Breathing
* 12.5: Irene M. Lang and Stephan Rosenkranz: Pulmonary hypertension
* 12.6: Silvia Priori, Alessandro Trancuccio, Alessia Chiara Latini,
Carlo Arnò, Deni Kukavica, and Andrea Mazzanti: Cardiac rhythm
disorders
* 12.7: Paulus Kirchhof, Andreas Metzner, Ruben Schleberger and Douglas
Packer: Management of atrial fibrillation in heart failure
* 12.8: Giuseppe Rosano, Javed Butler, Petar M. Seferovi?, Jelena
Seferovic and Francesco Cosentino: Diabetes, metabolic syndrome and
endocrine disorders
* 12.9: Giacomo De Luca, Luca Moroni, Alessandro Tomelleri, R
Marcolongo, Lorenzo Dagna, Alida LP Caforio, and Marco
Matucci-Cerinic: Systemic immune medicated diseases
* 12.10: Yuri Lopatin and Gianluigi Savarese: Liver and gut dysfunction
* 12.11: Ewa Jankowska, Piotr Ponikowski, and Stefan Anker: Anaemia and
iron deficiency
* 12.12: Wolfram Doehner, Cristiana Vitale, and Mehmet Birhan Yilmaz:
Depression and cognitive impairment
* 12.13: Alexander Lyon, Dimitrios Farmakis, Rudolf de Boer, and Yuri
Belenkov: Cancer
* 12.14: Johann Bauersachs, Denise Hilfiker-Kleiner and Karen Sliwa:
Pregnancy
* 12.15: Ewa Jankowska, Cristiana Vitale and Dong-Ju Choi: Frailty
* Section 13: Self-care and patient education
* 13.1: Tiny Jaarsma, Loreena Hill, Ekaterini Lambrinou, Anna
Stromberg, and Tina Hansen: Self-care and patient education
* Section 14: Multidisciplinary approach to heart failure management
* 14.1: Loreena Hill, Friedrich Koehler, Tiny Jaarsma, Marija Polovina,
Katherine McCreary, and Andrew JS Coats: Multidisciplinary approach
to heart failure management
* Section 15: Clinical trial design and interpretation
* 15.1: Gianluigi Savarese, Marija Polovina and Gerasimos Filippatos:
Clinical trial design and interpretation
* Section 16: Digital health in heart failure
* 16.1: Arvind Singhal and Martin Cowie: Digital health in heart
failure
* Section 17: Big data in heart failure
* 17.1: Mamas Mamas and Dipak Kotecha: Big data in heart failure
* Section 18: Telemedicine and remote monitoring
* 18.1: Tarek Bekfani, Friedrich Koehler and William T. Abraham:
Telemedicine and remote monitoring